DFTX (Definium Therapeutics) Current Accrued Expense: $17.10 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DFTX Definium Therapeutics Inc DFTX
28 GF Score
Price $41.92
! 5 Warning Signs
View Full Analysis

What is Definium Therapeutics Current Accrued Expense?

Definium Therapeutics DFTX -3.68% 28 Current Accrued Expense is $17.10 Mil as of Mar. 2026. GuruFocus rates DFTX with a GF Score™ of 28/100. The stock has 5 warning signs investors should review.

Definium Therapeutics's Current Accrued Expense for the quarter that ended in Mar. 2026 was $17.10 Mil.

Definium Therapeutics's quarterly Current Accrued Expense declined from Sep. 2025 ($11.70 Mil) to Dec. 2025 ($10.98 Mil) but then increased from Dec. 2025 ($10.98 Mil) to Mar. 2026 ($17.10 Mil).

Definium Therapeutics's annual Current Accrued Expense increased from Dec. 2023 ($4.27 Mil) to Dec. 2024 ($6.42 Mil) and increased from Dec. 2024 ($6.42 Mil) to Dec. 2025 ($10.98 Mil).

Definium Therapeutics Current Accrued Expense Related Terms

Definium Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Definium Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Definium Therapeutics Current Accrued Expense Chart

Definium Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 3.22 1.11 4.27 6.42 10.98

Definium Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.14 9.62 11.70 10.98 17.10
DFTX
28GF Score
Definium Therapeutics Inc DFTX
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Definium Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $17.10 Mil mean?
Definium Therapeutics (DFTX) has a Current Accrued Expense of $17.10 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Definium Therapeutics and its competitors.
Is Definium Therapeutics' Current Accrued Expense too high?
Definium Therapeutics' current Current Accrued Expense is $17.10 Mil. Overall, Definium Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Definium Therapeutics' Current Accrued Expense compare to SRRK and DNTH?
Definium Therapeutics' Current Accrued Expense of $17.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Definium Therapeutics and its competitors. Definium Therapeutics's current Current Accrued Expense is $17.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Definium Therapeutics stock overvalued right now?
Definium Therapeutics (DFTX) has a current Current Accrued Expense of $17.10 Mil. The current Current Accrued Expense is $17.10 Mil. Definium Therapeutics' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Definium Therapeutics (DFTX), the current Current Accrued Expense is $17.10 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Definium Therapeutics Business Description

Other Exchanges MMQ0:Germany
Address One World Trade Center, Suite 8500, New York, NY, USA, 10007
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
28GF Score

Get the complete analysis for DFTX

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.92
Price